OBJECTIVES: The aim of this study was to correlate the prostate-specific antigen (PSA) level and Gleason score with staging bone scan result in patients with a new diagnosis of prostate cancer in order to establish the feasibility of implementing the European Association Urology guidelines, which state that a bone scan may not be indicated when PSA <20 in well-moderately differentiated tumours. METHODS: We identified 633 patients retrospectively and 186 patients prospectively with a new diagnosis of prostate cancer undergoing a staging bone scan between March 2005 and January 2010. Patients were excluded if there was no Gleason score available or if the PSA level was checked over 3 months prior to bone scan. Bone scan results were analysed with respect to age, PSA level and Gleason score. In the case of an equivocal result, subsequent imaging was taken into consideration or the initial bone scan was re-reviewed. In persistently equivocal cases, all relevant imaging was assessed by a blinded panel of radiologists to allow a final decision to be made. RESULTS: Of 672 patients aged 39-93 years (median 71 years), who fulfilled the inclusion criteria, 54 (8%) had evidence of bony metastases. PSA level and Gleason score were both independent predictors of bone scan positivity and their predictive value was additive p<0.01. None of the 357 patients with a PSA level of <20 and a Gleason score of <8 had a positive bone scan. CONCLUSION: Staging bone scans in newly diagnosed prostate cancer patients with a PSA level of <20 and a Gleason score of <8 can be safely omitted, with these criteria having a negative predictive value of 100% in our series.
OBJECTIVES: The aim of this study was to correlate the prostate-specific antigen (PSA) level and Gleason score with staging bone scan result in patients with a new diagnosis of prostate cancer in order to establish the feasibility of implementing the European Association Urology guidelines, which state that a bone scan may not be indicated when PSA <20 in well-moderately differentiated tumours. METHODS: We identified 633 patients retrospectively and 186 patients prospectively with a new diagnosis of prostate cancer undergoing a staging bone scan between March 2005 and January 2010. Patients were excluded if there was no Gleason score available or if the PSA level was checked over 3 months prior to bone scan. Bone scan results were analysed with respect to age, PSA level and Gleason score. In the case of an equivocal result, subsequent imaging was taken into consideration or the initial bone scan was re-reviewed. In persistently equivocal cases, all relevant imaging was assessed by a blinded panel of radiologists to allow a final decision to be made. RESULTS: Of 672 patients aged 39-93 years (median 71 years), who fulfilled the inclusion criteria, 54 (8%) had evidence of bony metastases. PSA level and Gleason score were both independent predictors of bone scan positivity and their predictive value was additive p<0.01. None of the 357 patients with a PSA level of <20 and a Gleason score of <8 had a positive bone scan. CONCLUSION: Staging bone scans in newly diagnosed prostate cancerpatients with a PSA level of <20 and a Gleason score of <8 can be safely omitted, with these criteria having a negative predictive value of 100% in our series.
Authors: N Lee; R Fawaaz; C A Olsson; M C Benson; D P Petrylak; P B Schiff; E Bagiella; A Singh; R D Ennis Journal: Int J Radiat Oncol Biol Phys Date: 2000-12-01 Impact factor: 7.038
Authors: May Sadik; Madis Suurkula; Peter Höglund; Andreas Järund; Lars Edenbrandt Journal: Eur J Nucl Med Mol Imaging Date: 2008-03-29 Impact factor: 9.236
Authors: Alberto Briganti; Niccolò Passoni; Matteo Ferrari; Umberto Capitanio; Nazareno Suardi; Andrea Gallina; Luigi Filippo Da Pozzo; Maria Picchio; Valerio Di Girolamo; Andrea Salonia; Liugi Gianolli; Cristina Messa; Patrizio Rigatti; Francesco Montorsi Journal: Eur Urol Date: 2009-12-18 Impact factor: 20.096
Authors: Erik Rud; Daniyal Noor; Kristina Flor Galtung; Fredrik Ottosson; Maciej Jacewicz; Eduard Baco; Peter Mæhre Lauritzen Journal: Eur Radiol Date: 2022-08-08 Impact factor: 7.034
Authors: Selin Merdan; Paul R Womble; David C Miller; Christine Barnett; Zaojun Ye; Susan M Linsell; James E Montie; Brian T Denton Journal: Urology Date: 2014-08-02 Impact factor: 2.649
Authors: Ari Chong; Insang Hwang; Jung-Min Ha; Seong Hyeon Yu; Eu Chang Hwang; Ho Song Yu; Sun Ouck Kim; Seung-Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park Journal: Can Urol Assoc J Date: 2014-07 Impact factor: 1.862
Authors: Brian T Hanyok; Mary M Everist; Lauren E Howard; Amanda M De Hoedt; William J Aronson; Matthew R Cooperberg; Christopher J Kane; Christopher L Amling; Martha K Terris; Stephen J Freedland Journal: Asian J Urol Date: 2019-01-18